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Pseudomyogenic hemangioendothelioma (PHE)—previously re-
ferred to as a fibroma-like variant of epithelioid sarcoma, given its 
morphological similarity to epithelioid sarcoma —is a rare and re-
cently described endothelial tumor. According to the World Health 
Organization (WHO), PHE is a tumor of intermediate malignancy 
that rarely metastasizes (1). PHE is typically found in young adults, 
especially males (2, 3). Although it can be found in several loca-
tions, this tumor typically affects the extremities (mainly the low-
er limbs). It tends to be multifocal and to involve multiple tissue 
planes in the same anatomical region.
The case presented here of a young man diagnosed with PHE 
illustrates the importance of an adequate differential diagnosis in 
order to preserve the quality of life of patients whose PHE can be 
mistaken for more aggressive sarcomas.
Clinical case
A 34-year-old man presented to our department with multiple 
asymptomatic skin lesions on his left leg. These lesions had ap-
peared progressively over a 6-month period. There was no rele-
vant personal or family history.
A clinical observation revealed multiple brownish papules 
and plaques on the lateral and medial sides of the left leg (Fig. 
1). Some of these lesions had a hyperkeratotic surface and were 
tender and infiltrative on palpation. Because of the multifocality 
and the progressive appearance of newer lesions, a skin biopsy 
was performed on the same day.
Histologically, there was a moderately to highly cellular neo-
plasm, located predominantly on the subcutaneous tissue and 
extending to the dermis (Fig. 2). It was composed of a fascicular 
proliferation of plump spindle cells and epithelioid cells with 
prominent nucleoli and brightly eosinophilic cytoplasm, mimick-
ing rhabdomyoblasts (Figs. 3 and 4).
The cells were arranged in disorganized bundles with a mod-
erate inflammatory infiltrate of mononuclear predominance and 
dense collagen bundles. The mitotic index was low, with only 2 per 
10 high-power fields identified. There was no evidence of necrosis.
Immunohistochemical analysis was performed and revealed 
strong and diffuse reactivity with keratins AE1/AE3, ERG, and FLI1 
in both the spindle and the epithelioid neoplastic cells. Markers of 
muscular differentiation (desmin, myogenin, MyoD1, and smooth-
muscle actin) and melanocytic markers (S100-protein, HMB-45, 
and melan-A) were negative. Keratins MNF116 and CAM5.2, epithe-
lial membrane antigen (EMA), CD31, and CD34 were also negative, 
as was CAMTA1, a recently described antibody expressed in epi-
thelioid hemangioendothelioma (Table 1 and Fig. 5).
The nuclei of neoplastic cells showed intact INI1 expression 
(Table 1). The combination of the clinical, morphological, and 
immunophenotypical aspects was consistent with a diagnosis of 
PHE. Routine blood tests and infectious serology demonstrated 
no abnormalities. A CT scan of the chest, abdomen, and pelvis 
was unremarkable.
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Figure 1 | Brownish papules and plaques on the left leg.
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A CT scan of the lower limbs showed two well-defined nodular 
lesions in the skin—extending to the subcutaneous fat—in the 
anterior and medial aspects of the left leg, measuring 7 mm and 11 
mm, respectively. Several intracortical lytic lesions in the middle 
third of the left tibia, with dimensions varying from 1 to 5 mm, 
were also found. A 3 cm nodule on the left soleus muscle was also 
suspected based on the scan.
After a multidisciplinary consultation with oncology, the pa-
tient was sent to the local oncology center, where, due to the char-
acteristic indolent behavior of the tumor, the patient undergoes 
strict and regular clinical and imagiological evaluations. Follow-
up with an MRI occurs every 4 months. The surgical approach is 
held in reserve in the event the lesions grow markedly or symp-
toms such as pain appear between two follow-up consultations.
Discussion
PHE is a rare tumor with fewer than 100 cases described in the 
literature. This tumor was probably first described by Mirra et al. 
in 1992 under the proposed name of fibroma-like variant of epithe-
lioid sarcoma (4). It was thought to be related to epithelioid sarco-
ma because of its multifocal presentation on a single limb, often 
with osseous involvement, and its myoid cytomorphology with 
keratin-positive spindle cells. Additional cases resulted in a better 
understanding of the nature of PHE, and it is now recognized that 
it is not related to epithelioid sarcoma but rather is an independ-
ent neoplasm with an endothelial nature. In 2011, Hornick et al. 
proposed the name pseudomyogenic endothelioma, which better 
suits this entity (3).
PHE typically occurs in young males and tends to arise on the 
lower limbs, although it can also be found on the upper limbs, 
trunk, or face (3, 5–7).
It is a clinically nonspecific tumor usually presenting as pap-
ules or nodules grouped in an anatomical region (2, 3, 8–10). A 


















Figure 2 | H&E (original magnification 20×). At scanning magnification, there is 





Figure 3 | H&E (original magnification 100×). The nodule is composed of spin-
dle cells with eosinophilic cytoplasm admixed with inflammatory cells (A) and 
epithelioid cells (B).
Figure 4 | H&E (original magnification 400×). Note the epithelioid cells with 
glassy eosinophilic cytoplasm and prominent nucleoli, somewhat mimicking 
rhabdomyoblasts.
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multifocal presentation is found in two-thirds of patients at the 
time of diagnosis, and PHE often affects multiple tissue planes in 
the same anatomical region (11). Although the skin—primarily the 
dermis and the subcutis—is the most commonly affected tissue, 
about half of patients with PHE have muscular lesions and anoth-
er 20% have osseous lesions (3). Approximately 50% of patients 
complain of painful nodules whereas the rest are asymptomatic 
(3). Due to the lack of specific clinical characteristics and the af-
fliction of different body tissues, these patients are evaluated by 
multiple medical specialties, including dermatology, orthopedic 
surgery, and plastic surgery.
Histologically, PHE is an infiltrative neoplasm, involving the 
middle and deep reticular dermis and extending to the subcuta-
neous tissue. It is composed of fascicles of plump spindle cells 
and clusters of epithelioid cells that have the round, ample eo-
sinophilic cytoplasm and prominent nucleoli characteristic of 
the so-called rhabdomyoblastic or pseudomyogenic morphology. 





Figure 5 | Immunophenotype of neoplastic cells with immunoperoxidase technique (original magnification 100×). Both the epithelioid cells and spindle cells show 
diffuse immunoreactivity for keratin AE1/AE3 (A), FLI1 (B), and ERG (C). Unlike epithelioid sarcoma, there is intact expression of INI1 (D). There was no expression 
of CD34; note the expression in the endothelial cells as an internal control (E). Neoplastic cells were also negative for CAMTA1 (F).
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totic figures are usually low, usually less than 2 or 3 per 10 high-
power fields (2–4).
Immunohistochemical analysis demonstrates the expression 
of keratins AE1/AE3, CD31, ERG, and FLI1 by both the spindle and 
the epithelioid neoplastic cells, with variable focal and weaker 
immunoreactivity for CAM5.2, smooth muscle actin, epithelial 
membrane antigen, and pan-cytokeratin MNF116, and usually no 
expression of CD34, desmin, and S100-protein.
In PHE the expression of INI1 (SNF5/SMARCB1) is intact, mak-
ing it an important antibody for making the differential diagnosis 
with epithelioid sarcoma, which characteristically loses the reac-
tivity with INI1. This differential diagnosis is particularly impor-
tant because it has prognostic and therapeutic implications (2).
Although the histogenesis is still not clear, the expression of 
CD31, FLI1, and ERG—together with the clinical history and be-
havior—suggests that PHE might be a vascular neoplasm of inter-
mediate biologic potential (3).
A specific SERPINE1-FOSB fusion derived from t(7;19)(q22;q13) 
was identified and established PHE as a genetically distinct entity 
(5, 12, 13). The strong nuclear expression of FOSB on immunohis-
tochemistry in the tumor cells was demonstrated, enriching the 
panel of antibodies useful for the diagnosis of these tumors (5).
The main differential diagnoses of PHE include epithelioid sar-
coma, epithelioid hemangioendothelioma, and epithelioid angio-
sarcoma.
Epithelioid sarcoma shares some clinical and morphologic fea-
tures with PHE despite the different biologic behaviors. Epithe-
lioid sarcoma metastasizes to the lymph nodes and lung in 40% 
to 50% of cases, whereas PHE shows a significant risk for locore-
gional recurrence but a low potential for distant metastasis (2). 
The immunohistochemical panel is quite distinct: PHE expresses 
CD31, ERG, FLI1, and FOSB, whereas epithelioid sarcoma is nega-
tive for these antibodies. Epithelioid sarcoma cells characteristi-
cally lose the expression of INI1 that remains intact in PHE neo-
plastic cells (12).
Epithelioid hemangioendothelioma is a low-grade malignant 
vascular neoplasm composed of anastomosing cords of epithe-
lioid cells, with prominent cytoplasmic vacuolization, in a char-
acteristic myxohyaline stroma (1). Epithelioid hemangioendothe-
lioma usually expresses CD31, CD34, FLI1, and ERG, and shows 
reactivity for cytokeratins in 25 to 50% of tumors.
Epithelioid hemangioendothelioma has a characteristic trans-
location t(1;3) (p36.3;q25), which fuses the CAMTA1 gene on 
1p36.26 to the WWTR1 gene on 3q25.1 (1, 14). Additionally, the nu-
clear expression of CAMTA1 by immunohistochemistry is identi-
fied in the majority of epithelioid hemangioendothelioma cases, 
whereas other epithelioid mesenchymal neoplasms, including 
pseudomyogenic hemangioendothelioma, are negative for CAM-
TA1 (13).
Epithelioid angiosarcoma is a high-grade malignant vascular 
tumor usually located in the deep soft tissue and composed of epi-
thelioid endothelial cells with prominent atypia, a high nuclear 
grade, and frequent mitotic figures. Epithelioid angiosarcoma 
expresses vascular markers like CD31, CD34, ERG, and FLI1, and 
some tumors express cytokeratins, although this is usually a focal 
expression (1, 14).
The main treatment for PHE remains surgical excision of the 
lesions, even when there are multiple lesions, and sometimes am-
putation is needed to control the disease (2, 3, 6, 7, 11, 15). Related 
to the characteristic SERPINE1-FOSB fusion of PHE, IJzendoorn et 
al. recently reported the durable, complete remission of a patient 
with advanced unresectable PHE treated with telatinib (16). The 
authors concluded that telatinib (or other VEGFR1-4/PDGFRA in-
hibitors) could be a highly specific treatment option for patients 
with multifocal unresectable PHE (16).
Other less commonly used therapeutic options include radio-
therapy—mostly postsurgical—and chemotherapy with various cy-
totoxic regimens and resulting in heterogenic responses (2, 3, 11).
According to the latest WHO classification of soft tissues and 
bone tumors, PHE is a vascular tumor of intermediate malignancy 
that rarely metastasizes (1). Indeed, in the largest series of PHE 
described in the literature, only 1 out of 50 patients reported re-
gional lymph node metastasis and only 1 out of 50 patients de-
veloped distant metastases and eventually died of the disease (3). 
The same study reported a recurrence rate of nearly 60%, and the 
vast majority occurred within 1 year of the initial presentation.
In the light of this clinical behavior, long-term clinical and ra-
diologic follow-up is recommended to determine the presence of 
new nodules or local recurrence (3, 6).
Conclusion
In conclusion, this case of PHE highlights its typical multifocal 
presentation in a young man, the lack of characteristic clinical 
findings, and the importance of histological and immunopheno-
typical study. Multiple medical specialists should be aware of the 
existence of this recently described entity. The authors present 
this case because of its rarity and to draw attention to the exist-
ence of this recently described and still poorly characterized tu-
mor that often manifests with skin lesions.
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